Evaluating hyperandrogenism: A challenge in acne management

Journal of Drugs in Dermatology

Volumn 7, Issue 6, 2008, Pages 527-530

  Harper, Julie C ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; HYDROXYPROGESTERONE; PRASTERONE; TESTOSTERONE;

ACNE VULGARIS; ARTICLE; BLOOD; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; HYPERANDROGENISM; MALE;

17-ALPHA-HYDROXYPROGESTERONE; ACNE VULGARIS; ANDROGENS; DEHYDROEPIANDROSTERONE; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; HYPERANDROGENISM; MALE; TESTOSTERONE;

EID: 47249120731     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Lucky A, Biro FM, Huster GA, et al. Acne vulgaris in premarchal girls. Arch Dermatol. 1994;130:308-314.
2. Arowojolu AO, Gallo MF, Grimes DA, et al. Combined oral contraceptive pills for treatment of acne. The Cochrane Database of Systemic Reviews 2004, Issue 3. Art No: CD004425.DOI:10.1002/ 14651858.CD004425.pub2.
3. Azziz R, Sanchez LA, Knochenhauer ES, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab. 2004;89:453-462. (Pubitemid 38269843)
4. Lehucher-Ceyrac D, Chaspoux C, Weber MJ, et al. Acne, hyperandrogenism and oral isotretinoin resistance. Ann Dermatol Venereol. 1997;124:692-695.
5. Yildiz BO. Diagnosis of hyperandrogenism: clinical criteria. Best Pract Res Clin Endocrinol Metab. 2006;20:167-176. (Pubitemid 43842922)
6. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007;370:685-697. (Pubitemid 47285318)
7. New M. Nonclassical 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2006;91:4205-4214.
8. Chaspoux C, Lehucher-Ceyrac D, Morel P, et al. Acne in the male resistant to isotretinoin and responsibility of androgens. Ann Dermatol Venereol. 1999.126:17-19.
9. Polepalle S, Shabaik A, Alagiri M. Leydig cell tumor in a child with spermatocyte maturation and no pseudoprecocious puberty. Urology. 2003;62:551vi-551vii.
10. Naughton CK, Nadler RB, Basler JW, Humphrey PA. Leydig cell hyperplasia. Br J Urol. 1998;81:282-289. (Pubitemid 28316466)
11. Stanczyk F. Diagnosis of hyperandrogenism: biochemical criteria. Best Pract Res Clin Endocrinol Metab. 2006;20:177-191. (Pubitemid 43842929)
12. Lucky A, Rosenfield R, McGuire J, et al. Adrenal androgen hyperresponsiveness to adrenocorticotropin in women with acne and/or hirsutism: adrenal enzyme defects and exaggerated adrenarche. J Clin Endocrinol Metab. 1986;62:840-848. (Pubitemid 16106706)
13. Samuels MH. Cushing's syndrome and the nodular adrenal gland. Endocrin Metab Clin North Am. 1994;23:555-569. (Pubitemid 24300126)
14. Cordera F, Grant C, vanHeerden J, et al. Androgen-secreting adrenal tumors. Surgery. 2003;134:874-80.
15. Kaltsas G, Isidori A, Kola B, et al. The value of the low-dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women. J Clin Endocrinol Metab. 2003;88:2634-2643. (Pubitemid 36724436)
16. Aiman J. Virilizing ovarian tumors. Clin Obstet Gynecol. 1991;34: 835-847.
17. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Fertil Steril. 2004;81:19-25.
18. Melnik B, Jansen T, Grabbe S. Abuse of anabolic androgenic steroids and body building acne: an underestimated health problem. J Dtsch Dermatol Ges. 2007;5:110-117. (Pubitemid 46212727)
19. Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004;34:513-354.
20. Harwood K, Vuguin P, DiMartino-Nardi J. Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth. Horm Res. 2007;68:209-217. (Pubitemid 47525222)